Xavier Rossello1, Sergio Raposeiras-Roubin2, Belén Oliva3, Fátima Sánchez-Cabo3, José M García-Ruíz4, Francisca Caimari5, José M Mendiguren6, Enrique Lara-Pezzi4, Héctor Bueno7, Leticia Fernández-Friera8, Antonio Fernández-Ortiz9, Javier Sanz10, Borja Ibanez11, Valentin Fuster12. 1. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades CardioVasculares, Madrid, Spain; Cardiology Department, Health Research Institute of the Balearic Islands (IdISBa), Hospital Universitari Son Espases, Palma, Spain. Electronic address: https://twitter.com/RosselloXavier. 2. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Cardiology Department, University Hospital Álvaro Cunqueiro, Vigo, Spain. 3. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. 4. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades CardioVasculares, Madrid, Spain. 5. Endocrinology & Diabetes Department, Hospital Juaneda Miramar, Palma, Spain. 6. Banco de Santander, Madrid, Spain. 7. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. 8. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades CardioVasculares, Madrid, Spain; Hospital Universitario HM Montepríncipe-Centro Integral de Enfermedades Cardiovasculares, Madrid, Spain; Universidad CEU San Pablo, Madrid, Spain. 9. CIBER de Enfermedades CardioVasculares, Madrid, Spain; Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA. 10. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades CardioVasculares, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA. 11. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades CardioVasculares, Madrid, Spain; IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain. Electronic address: bibanez@cnic.es. 12. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: vfuster@cnic.es.
Abstract
BACKGROUND: The metabolic injury caused by protein glycation, monitored as the level of glycated hemoglobin (HbA1c), is not represented in most risk scores (i.e., Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease risk scale). OBJECTIVES: The purpose of this study was to assess the association between HbA1c and the extent of subclinical atherosclerosis (SA) and to better identify individuals at higher risk of extensive SA using HbA1c on top of key cardiovascular risk factors (CVRFs). METHODS: A cohort of 3,973 middle-aged individuals from the PESA (Progression of Early Subclinical Atherosclerosis) study, with no history of cardiovascular disease and with HbA1c in the nondiabetic range, were assessed for the presence and extent of SA by 2-dimensional vascular ultrasound and noncontrast cardiac computed tomography. RESULTS: After adjusting for established CVRFs, HbA1c showed an association with the multiterritorial extent of SA (odds ratio: 1.05, 1.27, 1.27, 1.36, 1.80, 1.87, and 2.47 for HbA1c 4.9% to 5.0%, 5.1% to 5.2%, 5.3% to 5.4%, 5.5% to 5.6%, 5.7% to 5.8%, 5.9% to 6.0%, and 6.1% to 6.4%, respectively; reference HbA1c ≤4.8%; p < 0.001). The association was significant in all pre-diabetes groups and even below the pre-diabetes cut-off (HbA1c 5.5% to 5.6% odds ratio: 1.36 [95% confidence interval: 1.03 to 1.80]; p = 0.033). High HbA1c was associated with an increased risk of SA in low-risk individuals (p < 0.001), but not in moderate-risk individuals (p = 0.335). Relative risk estimations using Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease predictors confirmed that inclusion of HbA1c modified the risk of multiterritorial SA in most risk categories. CONCLUSIONS: Routine use of HbA1c can identify asymptomatic individuals at higher risk of SA on top of traditional CVRFs. Lifestyle interventions and novel antidiabetic medications might be considered to reduce both HbA1c levels and SA in individuals without diabetes.
BACKGROUND: The metabolic injury caused by protein glycation, monitored as the level of glycated hemoglobin (HbA1c), is not represented in most risk scores (i.e., Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease risk scale). OBJECTIVES: The purpose of this study was to assess the association between HbA1c and the extent of subclinical atherosclerosis (SA) and to better identify individuals at higher risk of extensive SA using HbA1c on top of key cardiovascular risk factors (CVRFs). METHODS: A cohort of 3,973 middle-aged individuals from the PESA (Progression of Early Subclinical Atherosclerosis) study, with no history of cardiovascular disease and with HbA1c in the nondiabetic range, were assessed for the presence and extent of SA by 2-dimensional vascular ultrasound and noncontrast cardiac computed tomography. RESULTS: After adjusting for established CVRFs, HbA1c showed an association with the multiterritorial extent of SA (odds ratio: 1.05, 1.27, 1.27, 1.36, 1.80, 1.87, and 2.47 for HbA1c 4.9% to 5.0%, 5.1% to 5.2%, 5.3% to 5.4%, 5.5% to 5.6%, 5.7% to 5.8%, 5.9% to 6.0%, and 6.1% to 6.4%, respectively; reference HbA1c ≤4.8%; p < 0.001). The association was significant in all pre-diabetes groups and even below the pre-diabetes cut-off (HbA1c 5.5% to 5.6% odds ratio: 1.36 [95% confidence interval: 1.03 to 1.80]; p = 0.033). High HbA1c was associated with an increased risk of SA in low-risk individuals (p < 0.001), but not in moderate-risk individuals (p = 0.335). Relative risk estimations using Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease predictors confirmed that inclusion of HbA1c modified the risk of multiterritorial SA in most risk categories. CONCLUSIONS: Routine use of HbA1c can identify asymptomatic individuals at higher risk of SA on top of traditional CVRFs. Lifestyle interventions and novel antidiabetic medications might be considered to reduce both HbA1c levels and SA in individuals without diabetes.
Authors: Emily Keyes; Madison Grinnell; Douglas Jacoby; Thomas Vazquez; DeAnna Diaz; Victoria P Werth; Kevin Jon Williams Journal: Int J Womens Dermatol Date: 2021-09-09
Authors: Christoph Sinning; Nataliya Makarova; Stefan Söderberg; Marco M Ferrario; Barbara Thorand; Henry Völzke; Renate B Schnabel; Francisco Ojeda; Marcus Dörr; Stephan B Felix; Wolfgang Koenig; Annette Peters; Wolfgang Rathmann; Ben Schöttker; Hermann Brenner; Giovanni Veronesi; Giancarlo Cesana; Paolo Brambilla; Tarja Palosaari; Kari Kuulasmaa; Inger Njølstad; Ellisiv Bøgeberg Mathiesen; Tom Wilsgaard; Stefan Blankenberg Journal: Cardiovasc Diabetol Date: 2021-11-15 Impact factor: 9.951
Authors: Tamar S Polonsky; Amit Khera; Michael D Miedema; Douglas D Schocken; Peter W F Wilson Journal: J Am Heart Assoc Date: 2022-07-04 Impact factor: 6.106
Authors: Debasish Kar; Aya El-Wazir; Gayathri Delanerolle; Anna Forbes; James P Sheppard; Mintu Nath; Mark Joy; Nicholas Cole; J Ranjit Arnold; Andrew Lee; Michael Feher; Melanie J Davies; Kamlesh Khunti; Simon de Lusignan; Elizabeth Goyder Journal: EClinicalMedicine Date: 2022-07-02
Authors: Iryna Dykun; Ozgur Bayturan; Julie Carlo; Steven E Nissen; Samir R Kapadia; E Murat Tuzcu; Stephen J Nicholls; Rishi Puri Journal: Am J Prev Cardiol Date: 2022-01-18